A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult Participants
NCT ID: NCT05184452
Last Updated: 2025-02-10
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
95 participants
INTERVENTIONAL
2021-11-15
2023-07-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this part of the study is to understand how the body's immune system responds to a new lab-made antibody against HIV. The study is looking to see if the way the antibody is given affects the immune response. The study will also look at whether the antibody is safe to give to people and does not make them too uncomfortable.
Part B:
The purpose of this part of the study is to understand how the body's immune system responds to lab-made antibodies against HIV when they are given in combination at different doses. The study also wants to see if the way the antibodies are given affects the immune response.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Combinations of Monoclonal Antibodies PGT121, PGDM1400, 10-1074, and VRC07-523LS Administered Via Intravenous Infusion in Healthy, HIV-uninfected Adult Participants
NCT03928821
3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals
NCT04250636
Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults
NCT02797171
Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
NCT01565889
TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.
NCT00245739
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There are 2 parts of this study, Part A and Part B. About 15 people will take part in Part A of this study to test one study antibody. After early safety results from Part A are obtained, a decision will be made as to whether or not to do Part B of the study. Part B of the study would test a combination of 3 antibodies. If it is decided to move forward with Part B, 80 more people will join.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PGDM1400LS 5 mg/kg IV
Participants will receive PGDM1400LS 5 mg/kg by intravenous (IV) infusion at Month 0
PGDM1400LS (5mg/kg, IV)
5 mg/kg to be administered via IV infusion
PGDM1400LS 20 mg/kg IV
Participants will receive PGDM1400LS 20 mg/kg by IV infusion at Month 0
PGDM1400LS (20mg/kg, IV)
20 mg/kg to be administered via IV infusion
PGDM1400LS 20 mg/kg SC
Participants will receive PGDM1400LS 20 mg/kg by subcutaneous (SC) infusion at Month 0
PGDM1400LS (20mg/kg, SC)
20 mg/kg to be administered via SC infusion
PGDM1400LS 40 mg/kg IV
Participants will receive PGDM1400LS 40 mg/kg by IV infusion at Month 0
PGDM1400LS (40mg/kg, IV)
40 mg/kg to be administered via IV infusion
PGDM1400LS 40 mg/kg SC
Participants will receive PGDM1400LS 40 mg/kg by SC infusion at Month 0
PGDM1400LS (40mg/kg, SC)
40 mg/kg to be administered via SC infusion
PGDM1400LS 20mg/kg + VRC07-523LS 20mg/kg + PGT121.414.LS 20 mg/kg IV
Participants will receive PGDM1400LS 20mg/kg + VRC07-523LS 20mg/kg + PGT121.414.LS 20 mg/kg by IV infusion sequentially in this order at Month 0 and Month 4
PGDM1400LS (20mg/kg, IV)
20 mg/kg to be administered via IV infusion
VRC07-523LS (20mg/kg, IV)
VRC07-523LS 20mg/kg administered via IV infusion
PGT121.414.LS (20mg/kg, IV)
PGT121.414.LS 20mg/kg administered via IV infusion
PGDM1400LS 20mg/kg + VRC07-523LS 20mg/kg + PGT121.414.LS 20 mg/kg SC
Participants will receive PGDM1400LS 20mg/kg + VRC07-523LS 20mg/kg + PGT121.414.LS 20 mg/kg by SC infusion sequentially in this order at Month 0 and Month 4
PGDM1400LS (20mg/kg, SC)
20 mg/kg to be administered via SC infusion
VRC07-523LS (20mg/kg, SC)
VRC07-523LS 20mg/kg administered via SC infusion
PGT121.414.LS (20mg/kg, SC)
PGT121.414.LS 20mg/kg administered via SC infusion
PGDM1400LS 1.4gram + VRC07-523LS 1.4gram + PGT121.414.LS 1.4gram IV
Participants will receive PGDM1400LS 1.4gram + VRC07-523LS 1.4gram + PGT121.414.LS 1.4gram by IV infusion sequentially in this order at Month 0 and Month 4
PGDM1400LS (1.4g, IV)
1.4gram to be administered via IV infusion
VRC07-523LS (1.4g, IV)
VRC07-523LS 1.4g administered via IV infusion
PGT121.414.LS (1.4g, IV)
PGT121.414.LS 1.4g administered via IV infusion
PGDM1400LS 1.4gram + VRC07-523LS 1.4gram + PGT121.414.LS 1.4gram SC
Participants will receive PGDM1400LS 1.4gram + VRC07-523LS 1.4gram + PGT121.414.LS 1.4gram by SC infusion sequentially in this order at Month 0 and Month 4
PGDM1400LS (1.4g, SC)
1.4gram to be administered via SC infusion
VRC07-523LS (1.4g, SC)
VRC07-523LS 1.4g administered via SC infusion
PGT121.414.LS (1.4g, SC)
PGT121.414.LS 1.4g administered via SC infusion
PGDM1400LS 40mg/kg + VRC07-523LS 40mg/kg + PGT121.414.LS 40 mg/kg IV
Participants will receive PGDM1400LS 40mg/kg + VRC07-523LS 40mg/kg + PGT121.414.LS 40 mg/kg by IV infusion sequentially in this order at Month 0 and Month 4
PGDM1400LS (40mg/kg, IV)
40 mg/kg to be administered via IV infusion
VRC07-523LS (40mg/kg, IV)
VRC07-523LS 40mg/kg administered via IV infusion
PGT121.414.LS (40mg/kg, IV)
PGT121.414.LS 40mg/kg administered via IV infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PGDM1400LS (5mg/kg, IV)
5 mg/kg to be administered via IV infusion
PGDM1400LS (20mg/kg, IV)
20 mg/kg to be administered via IV infusion
PGDM1400LS (20mg/kg, SC)
20 mg/kg to be administered via SC infusion
PGDM1400LS (40mg/kg, IV)
40 mg/kg to be administered via IV infusion
PGDM1400LS (40mg/kg, SC)
40 mg/kg to be administered via SC infusion
PGDM1400LS (1.4g, IV)
1.4gram to be administered via IV infusion
PGDM1400LS (1.4g, SC)
1.4gram to be administered via SC infusion
VRC07-523LS (20mg/kg, IV)
VRC07-523LS 20mg/kg administered via IV infusion
VRC07-523LS (20mg/kg, SC)
VRC07-523LS 20mg/kg administered via SC infusion
VRC07-523LS (1.4g, IV)
VRC07-523LS 1.4g administered via IV infusion
VRC07-523LS (1.4g, SC)
VRC07-523LS 1.4g administered via SC infusion
VRC07-523LS (40mg/kg, IV)
VRC07-523LS 40mg/kg administered via IV infusion
PGT121.414.LS (20mg/kg, IV)
PGT121.414.LS 20mg/kg administered via IV infusion
PGT121.414.LS (20mg/kg, SC)
PGT121.414.LS 20mg/kg administered via SC infusion
PGT121.414.LS (1.4g, IV)
PGT121.414.LS 1.4g administered via IV infusion
PGT121.414.LS (1.4g, SC)
PGT121.414.LS 1.4g administered via SC infusion
PGT121.414.LS (40mg/kg, IV)
PGT121.414.LS 40mg/kg administered via IV infusion
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Access to a participating CRS and willingness to be followed for the planned duration of the study
3. Ability and willingness to provide informed consent
4. Assessment of understanding: volunteer demonstrates understanding of this study and completes a questionnaire prior to first study product administration with verbal demonstration of understanding of all questionnaire items answered incorrectly
5. Agrees not to enroll in another study of an investigational research agent until completion of the last required protocol clinic visit.
6. Good general health as shown by medical history, physical exam, and screening laboratory tests
7. Willingness to receive HIV test results
8. Willingness to discuss HIV infection risks and amenable to HIV risk reduction counseling.
9. Assessed by the clinic staff as being at "low risk" for HIV infection and committed to maintaining behavior consistent with low risk of HIV exposure through the last required protocol clinic visit (see Appendix J and Appendix K).
10. Hemoglobin
* ≥ 11.0 g/dL for volunteers who were assigned female sex at birth
* ≥ 13.0 g/dL for volunteers who were assigned male sex at birth and transgender males who have been on hormone therapy for more than 6 consecutive months
* ≥ 12.0 g/dL for transgender females who have been on hormone therapy for more than 6 consecutive months
* For transgender volunteers who have been on hormone therapy for less than 6 consecutive months, determine hemoglobin eligibility based on the sex assigned at birth
11. White blood cell count = 2,500 to 12,000 cells/mm3
12. WBC differential either within institutional normal range or with site clinician approval
13. Platelets = 125,000 to 550,000 cells/mm3
14. Chemistry panel: alanine aminotransferase (ALT) \< 1.25 times the institutional upper limit of normal (ie, \< 1.25 times the reference range upper limit) and creatinine \< 1.1 times the institutional upper limit of normal (ie, \<1.1 times the reference range upper limit)
15. Negative HIV-1 and -2 blood test: US volunteers must have a negative FDA-approved enzyme immunoassay (EIA) or chemiluminescent microparticle immunoassay (CMIA). Non-US sites may use locally available assays that have been approved by HVTN and HPTN Laboratory Operations
16. Negative Hepatitis B surface antigen (HBsAg)
17. Negative anti-Hepatitis C virus antibodies (anti-HCV), or negative HCV polymerase chain reaction (PCR) if the anti-HCV is positive
18. Negative or trace urine protein
19. Volunteers who were assigned female sex at birth: negative serum or urine beta human chorionic gonadotropin (β-HCG) pregnancy test(s) performed within 48 hours prior to initial study product administration. Persons who are NOT of reproductive potential due to having undergone total hysterectomy or bilateral oophorectomy (verified by medical records), are not required to undergo pregnancy testing.
20. A volunteer who was assigned female sex at birth must:
* Agree to use effective contraception for sexual activity that could lead to pregnancy from at least 21 days prior to enrollment through the last required protocol visit. Effective contraception is defined as using one of the following methods: Condoms (internal and external) with or without a spermicide, Diaphragm or cervical cap with spermicide, Intrauterine device (IUD), Hormonal contraception, Tubal ligation, or Any other contraceptive method approved by the HVTN 140/HPTN 101 PSRT, Successful vasectomy in any partner assigned male sex at birth (considered successful if a volunteer reports that a male partner has \[1\] documentation of azoospermia by microscopy, or \[2\] a vasectomy more than 2 years ago with no resultant pregnancy despite sexual activity postvasectomy); or,
* Not be of reproductive potential, such as having reached menopause (no menses for 1 year) or having undergone hysterectomy or bilateral oophorectomy; or,
* Be sexually abstinent.
21. Volunteers who were assigned female sex at birth must also agree not to seek pregnancy through alternative methods, such as artificial insemination or in vitro fertilization until after the last required protocol clinic visit
Exclusion Criteria
2. Blood products received within 120 days before first study product administration, unless eligibility for earlier enrollment is determined by the HVTN 140/HPTN 101 PSRT
3. Investigational research agents received within 30 days before first study product administration
4. Intent to participate in another study of an investigational research agent or any other study that requires non-Network HIV antibody testing during the planned duration of the HVTN 140/HPTN 101 study
5. Pregnant or breastfeeding
6. HIV vaccine(s) received in a prior HIV vaccine trial. Volunteers who have received control/placebo in an HIV vaccine trial are not excluded.
7. SARS-CoV-2 vaccine(s) received within 7 days prior to HVTN 140/HPTN 101 enrollment or planned within 7 days after enrollment.
8. Receipt of humanized or human mAbs, whether licensed or investigational.
9. Previous receipt of mAbs VRC01, VRC01LS, VRC07-523LS, PGDM1400, PGT121, PGT121.414.LS.
10. Immunosuppressive medications received within 30 days before first study product administration (Not exclusionary: \[1\] corticosteroid nasal spray; \[2\] inhaled corticosteroids; \[3\] topical corticosteroids for mild, uncomplicated dermatological condition; or \[4\] a single course of oral/parenteral prednisone or equivalent at doses \< 20 mg/day and length of therapy \< 14 days)
11. Serious adverse reactions to PGDM1400LS, VRC07-523LS, or PGT121.414.LS formulation components (see Section 8.2) including history of anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain.
12. Immunoglobulin received within 60 days before first study product administration (for mAb see criterion 8 above)
13. Autoimmune disease (Not excluded from participation: Volunteer with mild, stable and uncomplicated autoimmune disease that does not require immunosuppressive medication and that, in the judgment of the CRS investigator, is likely not subject to exacerbation and likely not to complicate Solicited and Unsolicited AE assessments.)
14. Immunodeficiency
15. Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health. A clinically significant condition or process includes but is not limited to:
* Symptoms consistent with COVID-19 or known SARS-CoV-2 infection,
* A process that would affect the immune response,
* A process that would require medication that affects the immune response,
* Any contraindication to repeated infusions, or blood draws, including inability to establish venous or subcutaneous access,
* A condition that requires active medical intervention or monitoring to avert grave danger to the volunteer's health or well-being during the study period,
* A condition or process (eg, chronic urticaria or recent injection or infusion with evidence of residual inflammation) for which signs or symptoms could be confused with reactions to the study product, or
16. Any medical, psychiatric, or skin condition (eg, tattoos), or occupational responsibility that, in the judgment of the investigator, would interfere with or serve as a contraindication to protocol adherence, assessment of safety or Solicited AEs, or a participant's ability to give informed consent.
17. Psychiatric condition that precludes compliance with the protocol. Specifically excluded are persons with psychoses within the past 3 years, ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years.
18. Current anti-tuberculosis (TB) therapy
19. Asthma other than mild, well-controlled asthma. (Symptoms of asthma severity as defined in the most recent National Asthma Education and Prevention Program (NAEPP) Expert Panel report).
Exclude a volunteer who:
* Uses a short-acting rescue inhaler (typically a beta 2 agonist) daily, or
* Uses moderate/high-dose, inhaled corticosteroids, or
* In the past year has had either of the following: Greater than 1 exacerbation of symptoms treated with oral/parenteral corticosteroids; Emergency care, urgent care, hospitalization, or intubation for asthma.
20. Diabetes mellitus type 1 or type 2 (Not excluded: type 2 cases controlled with diet alone or a history of isolated gestational diabetes.)
21. Hypertension:
* If a person has been found to have elevated blood pressure or hypertension during screening or previously, exclude for blood pressure that is not well controlled. Well-controlled blood pressure is defined in this protocol as consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic, with or without medication, with only isolated, brief instances of higher readings, which must be ≤ 150 mm Hg systolic and ≤ 100 mm Hg diastolic. For these volunteers, blood pressure must be ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic at enrollment.
* If a person has NOT been found to have elevated blood pressure or hypertension during screening or previously, exclude for systolic blood pressure ≥ 150 mm Hg at enrollment or diastolic blood pressure ≥ 100 mm Hg at enrollment.
22. Bleeding disorder diagnosed by a clinician (eg, factor deficiency, coagulopathy, or platelet disorder requiring special precautions)
23. Malignancy (Not excluded from participation: Volunteer who has had malignancy excised surgically and who, in the investigator's estimation, has a reasonable assurance of sustained cure, or who is unlikely to experience recurrence of malignancy during the period of the study)
24. Seizure disorder: History of seizure(s) within past 3 years. Also exclude if volunteer has used medications in order to prevent or treat seizure(s) at any time within the past 3 years.
25. Asplenia: any condition resulting in the absence of a functional spleen
26. History of generalized urticaria, angioedema, or anaphylaxis (Not exclusionary: angioedema or anaphylaxis to a known trigger with at least 5 years since last reaction to demonstrate satisfactory avoidance of trigger).
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
Department of Health and Human Services
FED
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Colleen Kelley
Role: STUDY_CHAIR
Emory University
Marc Siegel
Role: STUDY_CHAIR
George Washington University
Sharana Mahomed
Role: STUDY_CHAIR
Centre for the AIDS Programme of Research in South Africa
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bridge HIV CRS
San Francisco, California, United States
George Washington University
Washington D.C., District of Columbia, United States
The Hope Clinic of the Emory Vaccine Center
Atlanta, Georgia, United States
New Jersey Medical School Clinical Research Center CRS
Newark, New Jersey, United States
Vanderbilt Vaccine (VV)
Nashville, Tennessee, United States
Kenya Medical Research Institute (KEMRI)
Kericho, , Kenya
CAPRISA eThekweni Clinical Research Site
Berea, Durban, South Africa
Ward 21 Clinical Research Site
Hillbrow, Johannesburg, South Africa
Groote Schuur Hospital
Cape Town, Western Cape, South Africa
Soweto HVTN CRS
Soweto, , South Africa
Seke South Clinical Research Site
Chitungwiza, Harare, Zimbabwe
Milton Park CRS
Milton Park, Harare, Zimbabwe
Spilhaus CRS
Milton Park, Harare, Zimbabwe
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Seaton KE, Paez CA, Yu C, Karuna ST, Gamble T, Miner MD, Heptinstall J, Zhang L, Gao F, Yacovone M, Spiegel H, Dumond JB, Anderson M, Piwowar-Manning E, Dye B, Tindale I, Proulx-Burns L, Trahey M, Takuva S, Takalani A, Bailey VC, Kalams SA, Scott H, Mkhize NN, Weiner JA, Ackerman ME, McElrath MJ, Pensiero M, Barouch DH, Montefiori D, Tomaras GD, Corey L, Cohen MS, Huang Y, Mahomed S, Siegel M, Kelley CF; HVTN 140/HPTN 101 study team. Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trial. Lancet HIV. 2025 Jun;12(6):e405-e415. doi: 10.1016/S2352-3018(25)00012-8.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Informed Consent Form
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DAIDS DOCUMENT ID
Identifier Type: OTHER
Identifier Source: secondary_id
HVTN 140/HPTN 101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.